Antibe Therapeutics (ATBPF) Short Interest Ratio & Short Volume $0.22 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Antibe Therapeutics Short Interest DataAntibe Therapeutics (ATBPF) has a short interest of 65,100 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 27,352 shares to cover all short positions.Current Short Interest65,100 sharesPrevious Short Interest65,100 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$14,061.60Short Interest Ratio0.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares52,981,000 sharesPercentage of Shares Shorted0.12%Today's Trading Volume0 sharesAverage Trading Volume27,352 sharesToday's Volume Vs. Average0% Short Selling Antibe Therapeutics? Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATBPF Short Interest Over TimeATBPF Days to Cover Over TimeATBPF Percentage of Float Shorted Over Time Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Antibe Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 11/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 10/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 10/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 Get the Latest News and Ratings for ATBPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 6/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 6/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 4/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 4/15/202465,100 shares $14,035.56 +1,934.4%N/A0.7 $0.22 3/31/20243,200 shares $1,070.40 -64.0%N/A0.1 $0.33 3/15/20248,900 shares $2,891.61 -73.1%N/A0.1 $0.32 2/29/202433,100 shares $23,653.26 +234.3%N/A0.5 $0.71 2/15/20249,900 shares $6,811.20 No ChangeN/A0.6 $0.69 1/15/202410,400 shares $8,112.00 -9.6%N/A1.4 $0.78 12/31/202311,500 shares $7,843.00 +121.2%N/A0.7 $0.68 12/15/20235,200 shares $3,571.88 -17.5%N/A1.1 $0.69 11/30/20236,300 shares $3,433.50 -54.0%N/A0.8 $0.55 11/15/202313,700 shares $7,521.30 +17.1%N/A0.1 $0.55 10/31/202311,700 shares $5,382.00 -27.8%N/A0.2 $0.46 10/15/202316,200 shares $5,799.60 +211.5%N/A1.7 $0.36 9/30/20235,200 shares $1,863.06 -24.6%N/A0.2 $0.36 9/15/20236,900 shares $2,829.00 -76.4%N/A0.3 $0.41 8/31/202329,200 shares $11,554.44 -22.8%N/A1.1 $0.40 8/15/202337,800 shares $15,498.00 +563.2%N/A1.5 $0.41 7/31/20235,700 shares $2,053.14 -8.1%N/A0.4 $0.36 7/15/20236,200 shares $2,156.98 No ChangeN/A2.8 $0.35 6/30/20236,200 shares $2,170.00 -7.5%N/A2.6 $0.35 6/15/20236,700 shares $2,517.19 -71.7%N/A1.6 $0.38 5/31/202323,700 shares $8,752.41 +203.9%N/A1.3 $0.37 5/15/20237,800 shares $2,934.36 -27.8%N/A0.6 $0.38 4/30/202310,800 shares $4,342.68 -6.9%N/A3.1 $0.40 4/15/202311,600 shares $4,637.68 -78.6%N/A3.6 $0.40 3/31/202354,100 shares $23,766.13 -1.3%N/A2.5 $0.44We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol 3/15/202354,800 shares $20,643.16 +260.5%N/A1.2 $0.38 2/28/202315,200 shares $5,668.08 -37.5%N/A1.7 $0.37 2/15/202324,300 shares $10,529.19 +22.7%N/A4.9 $0.43 1/31/202319,800 shares $8,401.14 +94.1%N/A0.8 $0.42 1/15/202310,200 shares $5,115.81 -56.8%N/A4.3 $0.50 12/30/202223,600 shares $7,622.80 -23.1%N/A2.5 $0.32 12/15/202230,700 shares $11,666.00 +44.8%N/A2.8 $0.38 11/30/202221,200 shares $7,420.00 +32.5%N/A3.2 $0.35 11/15/202216,000 shares $5,912.00 +3.9%N/A1.3 $0.37 10/31/202215,400 shares $5,998.30 +12.4%N/A3.1 $0.39 10/15/202213,700 shares $5,555.35 -8.7%N/A3 $0.41 9/30/202215,000 shares $6,718.50 -41.4%N/A1.1 $0.45 9/15/202225,600 shares $12,170.24 -13.8%N/A2.8 $0.48 8/31/202229,700 shares $14,362.92 -15.1%N/A2.3 $0.48 8/15/202235,000 shares $17,570.00 -39.2%N/A3.3 $0.50 7/31/202257,600 shares $25,920.00 -26.9%N/A20.6 $0.45 7/15/202278,800 shares $37,248.76 +3.8%N/A17.1 $0.47 6/30/202275,900 shares $35,832.39 -5.8%N/A5.2 $0.47 6/15/202280,600 shares $38,833.08 +2.8%N/A6.3 $0.48 5/31/202278,400 shares $42,696.64 +5.0%N/A6.2 $0.54 5/15/202274,700 shares $39,591.00 +48.8%N/A6.2 $0.53 4/30/202250,200 shares $28,011.60 +8.9%N/A7 $0.56 4/15/202246,100 shares $27,293.51 +45.9%N/A3.7 $0.59 3/31/202231,600 shares $20,066.00 +3.3%N/A2.4 $0.64 3/15/202230,600 shares $17,448.12 -23.7%N/A1.6 $0.57 2/28/202240,100 shares $23,454.49 +74.4%N/A1.1 $0.58 2/15/202223,000 shares $12,811.00 +57.5%N/A1.5 $0.56 1/31/202214,600 shares $7,678.14 +630.0%N/A0.2 $0.53 1/15/20222,000 shares $1,115.80 -66.1%N/A0.1 $0.56 12/31/20215,900 shares $3,043.81 -65.7%N/A0.1 $0.52 12/15/202117,200 shares $8,536.36 -71.4%N/A0.4 $0.50 11/30/202160,100 shares $32,737.67 -41.1%N/A1.6 $0.54 11/15/2021102,000 shares $72,644.40 -42.3%N/A0.7 $0.71 10/29/2021176,800 shares $114,725.52 +665.4%N/A1.2 $0.65 10/15/202123,100 shares $18,225.90 +725.0%N/A0.4 $0.79 9/30/20212,800 shares $2,640.40 +180.0%N/A0 $0.94 9/15/20211,000 shares $948.40 +11.1%N/A0 $0.95 8/31/2021900 shares $900.00 -96.4%N/A0 $1.00 8/13/202124,700 shares $25,935.00 -88.2%N/A0.1 $1.05 7/30/2021208,400 shares $561,638.00 +10.7%N/A6.6 $2.70 7/15/2021188,200 shares $513,409.60 -0.1%N/A9.6 $2.73 6/30/2021188,300 shares $559,251.00 -3.7%N/A5.8 $2.97 6/15/2021195,500 shares $602,218.20 -8.2%N/A5.5 $3.08 5/28/2021212,900 shares $724,924.50 +8.0%N/A11 $3.41 5/14/2021197,200 shares $646,816.00 -5.6%N/A8.2 $3.28 4/30/2021208,900 shares $714,458.89 +6.8%N/A5.8 $3.42 4/15/2021195,600 shares $708,072.00 -12.6%N/A9.5 $3.62 3/31/2021223,700 shares $883,615.00 +41.5%N/A1.8 $3.95 3/15/2021158,100 shares $623,388.30 -54.4%N/A3.2 $3.94 2/26/2021346,600 shares $1.50 million +439.9%N/A2 $4.34We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol 2/12/202164,200 shares $301,098.00 -17.3%N/A0.5 $4.69 1/29/202177,600 shares $219,297.60 +21.1%N/A1.8 $2.83 12/31/202028,600 shares $89,518.00 No ChangeN/A0.5 $3.13 11/30/202030,700 shares $9,513.93 +332.4%N/A0.1 $0.31 11/15/20207,100 shares $2,188.93 -64.5%N/A0.1 $0.31 10/30/202020,000 shares $4,800.00 No ChangeN/A0.2 $0.24 10/15/202020,000 shares $5,342.00 +52.7%N/A0.2 $0.27 9/30/202013,100 shares $3,445.30 No ChangeN/A0 $0.26 8/31/20201,300 shares $388.96 -93.1%N/A0 $0.30 8/14/202018,900 shares $5,934.60 -44.9%N/A0 $0.31 7/31/202034,300 shares $9,569.70 +2,350.0%N/A0.1 $0.28 7/15/20201,400 shares $408.52 -92.4%N/A0 $0.29 6/30/202018,300 shares $5,574.18 -36.2%N/A0 $0.30 6/15/202028,700 shares $10,705.10 +135.3%N/A0 $0.37 5/29/202012,200 shares $3,782.00 +281.3%N/A0.1 $0.31 5/15/20203,200 shares $1,856.00 -98.3%N/A0 $0.58 4/30/2020191,600 shares $101,548.00 +787.0%N/A0.6 $0.53 4/15/202021,600 shares $10,584.00 -83.4%N/A0.1 $0.49 3/31/2020130,400 shares $70,416.00 -52.7%N/A0.3 $0.54 3/13/2020275,700 shares $137,850.00 +58.3%N/A0.6 $0.50 2/28/2020174,200 shares $64,454.00 +60.9%N/A0.8 $0.37 2/14/2020108,300 shares $49,818.00 -18.0%N/A0.2 $0.46 1/31/2020132,000 shares $62,040.00 +28.4%N/A0.4 $0.47 1/15/2020102,800 shares $49,344.00 -47.6%N/A0.3 $0.48 12/31/2019196,000 shares $76,440.00 -3.1%N/A1.4 $0.39 ATBPF Short Interest - Frequently Asked Questions What is Antibe Therapeutics' current short interest? Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 65,100 shares of ATBPF short. Learn More on Antibe Therapeutics' current short interest. How does Antibe Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: BioVie Inc. (10.36%), Gain Therapeutics, Inc. (2.31%), Rallybio Co. (1.75%), Q32 Bio Inc. (15.77%), Xilio Therapeutics, Inc. (0.85%), SCYNEXIS, Inc. (2.10%), Actinium Pharmaceuticals, Inc. (6.89%), Earth Science Tech, Inc. (0.01%), Clene Inc. (2.14%), Barinthus Biotherapeutics plc (0.04%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Antibe Therapeutics stock? Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Antibe Therapeutics? A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further. How often is Antibe Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies BioVie Short Interest Data Gain Therapeutics Short Interest Data Rallybio Short Interest Data Q32 Bio Short Interest Data Xilio Therapeutics Short Interest Data SCYNEXIS Short Interest Data Actinium Pharmaceuticals Short Interest Data Earth Science Tech Short Interest Data Clene Short Interest Data Barinthus Biotherapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATBPF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
